Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors.

Rats implanted with RG-2 gliomas were administered i.v. RMP-7 and [14C]carboplatin. Changes in the permeability of the blood-brain barrier to carboplatin were determined using quantitative autoradiography. i.v. infusions of RMP-7 induced an increase in the permeability of the vascular barrier within the tumor to carboplatin. Additionally, permeability of brain tissue proximal to, but clearly outside the tumor mass, was also increased. Progressively less uptake of [14C]carboplatin was observed as distance from the tumor border increased. The increases in permeability induced by RMP-7 occurred in a dose-related fashion. No increase in carboplatin level was observed in several nonbrain tissues, including sciatic nerve, retina, heart, lung, liver, kidney, and spleen. Finally, the permeabilizing effects of RMP-7 were shown to occur independent of histaminergic or hypotensive mechanisms. These data provide additional insight into the permeabilizing effects and mechanism of RMP-7 and offer additional support for the therapeutic utility of this novel compound as an adjunctive treatment for human gliomas.

[1]  S. Nutik,et al.  Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. , 1985, Journal of neurosurgery.

[2]  K. Wallner,et al.  Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. , 1989, International journal of radiation oncology, biology, physics.

[3]  R. Schilsky,et al.  Toxic effects of cis-dichlorodiammineplatinum(II) in man. , 1979, Cancer treatment reports.

[4]  K. Black,et al.  Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors , 1994, Brain Research.

[5]  K D Pettigrew,et al.  Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. , 1978, The American journal of physiology.

[6]  D. Robertson,et al.  Pharmacological Modification of Bradykinin Induced Breakdown of the Blood-brain Barrier , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[7]  R. Fishman Is there a therapeutic role for osmotic breaching of the blood—Brain barrier? , 1987, Annals of neurology.

[8]  Michael G. K. Jones,et al.  Selection of potential second generation platinum compounds , 1978 .

[9]  D. Long Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. , 1970, Journal of neurosurgery.

[10]  T. Reese,et al.  JUNCTIONS BETWEEN INTIMATELY APPOSED CELL MEMBRANES IN THE VERTEBRATE BRAIN , 1969, The Journal of cell biology.

[11]  J. Victor,et al.  Intra-arterial cisplatin--associated optic and otic toxicity. , 1992, Archives of neurology.

[12]  E P Frenkel,et al.  Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Rapoport,et al.  Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. , 1984, Federation proceedings.

[14]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[15]  C. Keele,et al.  The Principles of Chemotherapy , 1952, Postgraduate medical journal.

[16]  K. Black,et al.  Unlocking the Blood–Brain Barrier: A Role for RMP-7 in Brain Tumor Therapy , 1996, Experimental Neurology.

[17]  G. Goldstein,et al.  Hyperosmotic arabinose solutions open the tight junctions between brain capillary endothelial cells in tissue culture , 1984, Brain Research.

[18]  M. Rozencweig,et al.  Carboplatin: current status and future prospects. , 1988, Cancer treatment reviews.

[19]  R. Heller-Harrison,et al.  The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells. , 1994, The Journal of pharmacology and experimental therapeutics.

[20]  K. Black Biochemical opening of the blood-brain barrier. , 1995, Advanced drug delivery reviews.

[21]  D. Stewart,et al.  Phase I study of intracarotid administration of carboplatin. , 1992, Neurosurgery.

[22]  S. Rapoport Osmotic opening the blood‐brain barrier , 1988, Annals of neurology.

[23]  P. Devillier,et al.  Histamine release from rat peritoneal mast cells by kinin antagonists. , 1988, European journal of pharmacology.

[24]  M. Fukui,et al.  Intracarotid histamine infusion increases blood tumour permeability in RG2 glioma. , 1994, Neurological research.

[25]  Per Brodal,et al.  A stereotaxic atlas of the rat brain L. J. Pellegrino, A. S. Pellegrino & A. J. Cushman. Plenum Press, New York (1979). 122 Figures. £22.50 , 1980, Neuroscience.

[26]  E P Frenkel,et al.  Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. , 1984, Neurosurgery.

[27]  R. Bartus,et al.  Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7 , 1995, Brain Research.

[28]  R. Bartus,et al.  Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7. , 1996, Immunopharmacology.

[29]  J. Posner,et al.  Opening the blood–brain and blood–tumor barriers in experimental rat brain tumors: The effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow , 1986, Annals of neurology.

[30]  P. J. Hoopes,et al.  Central nervous system tumors. , 1995, Seminars in veterinary medicine and surgery.

[31]  L. V. van Putten,et al.  Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives. , 1984, European journal of cancer & clinical oncology.

[32]  D. Groothuis,et al.  The effect of graded hypertonic intracarotid infusions on drug delivery to experimental RG‐2 gliomas , 1984, Neurology.

[33]  W. T. Shults,et al.  Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. , 1986, American journal of ophthalmology.

[34]  S. Nishio,et al.  Hyperosmotic blood-brain barrier disruption in brains of rats with an intracerebrally transplanted RG-C6 tumor. , 1987, Journal of neurosurgery.

[35]  Fred H. Hochberg,et al.  Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.

[36]  F. Hazama,et al.  NEUROTOXICITY OF VINCRISTINE AFTER THE OSMOTIC OPENING OF THE BLOOD‐BRAIN BARRIER , 1983, Neuropathology and applied neurobiology.

[37]  W. Yung,et al.  Intravenous carboplatin for recurrent malignant glioma: a phase II study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Minna,et al.  Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. , 1985, Neurosurgery.

[39]  H. Landahl,et al.  Permeability characteristics of brain adjacent to tumors in rats. , 1975, Archives of neurology.

[40]  S. Green,et al.  A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. , 1992, Journal of neurosurgery.

[41]  Y. Z. Ziylan,et al.  Effect of Dexamethasone on Transport of α‐Aminoisobutyric Acid and Sucrose Across the Blood‐Brain Barrier , 1988, Journal of neurochemistry.

[42]  P. Gutin,et al.  Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. , 1990, International journal of radiation oncology, biology, physics.

[43]  P. J. Elliott,et al.  Controlled Modulation of BBB Permeability Using the Bradykinin Agonist, RMP-7 , 1996, Experimental Neurology.

[44]  K. Black,et al.  Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. , 1994, Journal of neurosurgery.

[45]  G. Lesser,et al.  The chemotherapy of high-grade astrocytomas. , 1994, Seminars in oncology.

[46]  M. Fukui,et al.  Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. , 1996, Neurosurgery.

[47]  F. Haddy,et al.  The Effect of the Kinins on the Cardiovascular System , 1970 .

[48]  W. Shapiro,et al.  Principles of brain tumor chemotherapy. , 1986, Seminars in oncology.

[49]  J. Dion,et al.  A Phase 1–2 Trial of Superselective Carboplatin, Low‐Dose Infusional 5‐Fluorouracil and Concurrent Radiation for High‐Grade Gliomas , 1995, American journal of clinical oncology.

[50]  K. Black,et al.  Bradykinin Selectively Opens Blood-Tumor Barrier in Experimental Brain Tumors , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[51]  M. Wahl,et al.  Opening of the blood-brain barrier during cortical superfusion with histamine , 1994, Brain Research.

[52]  M. Tableman,et al.  Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. , 1995, Neurosurgery.

[53]  W. Rose,et al.  ANTITUMOR ACTIVITY OF PLATINUM ANALOGS , 1980 .

[54]  D. Bigner,et al.  Permeability of Different Experimental Brain Tumor Models to Horseradish Peroxidase , 1982, Journal of neuropathology and experimental neurology.

[55]  E. G. Erdös,et al.  Release of Histamine from Mast Cells by Vasoactive Peptides 1 , 1973, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[56]  S. Rapoport,et al.  Osmotic opening of tight junctions in cerebral endothelium , 1973, The Journal of comparative neurology.